Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France

Penso, Laëtitia; Dray‐Spira, Rosemary; Weill, Alain; Zureik, Mahmoud; Sbidian, É.

doi:10.1111/bjd.20659

Cited by 12 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A French study assessed the outcome of COVID‐19 in adults with psoriasis from the national health insurance database and separately analysed the first and the second waves of the pandemic. 21 It found no difference in mortality between patients taking biologic vs. non‐biologic systemic drugs for both waves. They noted an increased risk of hospitalization for patients under non‐biologic systemic drugs during the first wave, without increased risk of mortality when compared to patients under biologic drugs.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Children with psoriasis and COVID‐19: factors associated with an unfavourable COVID‐19 course, and the impact of infection on disease progression (Chi‐PsoCov registry)

Zitouni

Bursztejn

Fortina

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background The COVID‐19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID‐19 could impact the course of psoriasis in children. Objectives The aim of this study was therefore to assess the impact of COVID‐19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. Methods We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID‐19 and had COVID‐19 with or without symptoms. Results One hundred and twenty episodes of COVID‐19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non‐biologic systemic drugs. COVID‐19 was confirmed in 106 children (88.3%) and 3 children had two COVID‐19 infections each. COVID‐19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non‐biologic systemic treatments ( P = 0.02) and without systemic treatment ( P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non‐biologic systemic treatment when compared with the other children ( P = 0.01), and particularly under methotrexate ( P = 0.03). After COVID‐19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID‐19, mainly a guttate form ( P = 0.01). Discussion Biologics appear to be safe with no increased risk of severe form of COVID‐19 in children with psoriasis. COVID‐19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Children with psoriasis and COVID‐19: factors associated with an unfavourable COVID‐19 course, and the impact of infection on disease progression (Chi‐PsoCov registry)

Zitouni

Bursztejn

Fortina

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The PMSI database contains details of all hospital admissions in France and hospital diagnoses according to the International Statistical Classification of Diseases and Related Health Problems (ICD‐10). These databases have been fully described elsewhere and are regularly used for the monitoring of drugs 11,12 …”

Section: Methodsmentioning

confidence: 99%

Profiles of copper intrauterine devices and levonorgestrel intrauterine systems users in France in 2019: A national observational population‐based study

Roland

Baricault²,

Dray‐Spira³

et al. 2022

Intl J Gynecology & Obste

Self Cite

View full text Add to dashboard Cite

show abstract

“…TNF inhibitors plus MTX in psoriasis patients showed no difference in severe COVID-19 infection, but in certain cohorts [ 38 , 39 ], this treatment showed a decreased risk of COVID-19 infection and COVID-19-related mortality among IMID patients. Recent studies showed that non-biologics- or biologics-treated psoriasis patients with positive COVID-19 showed a decreased risk of severe COVID-19 infection [ 39 , 40 , 41 ]. These results suggest that IMIDs other than psoriasis treated with non-biologics may have an increased risk of severe COVID-19, while psoriasis patients are not at a higher risk of severe COVID-19 infection when treated either with biologics or non-biologics.…”

Section: Inflammation Exacerbates Covid-19 Infectionmentioning

confidence: 99%

Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?

Komine

Ansary

Hossain

et al. 2022

IJMS

View full text Add to dashboard Cite

COVID-19 is a recently emerged viral infection worldwide. SARS-CoV-2, the causative virus, is believed to have emerged from bat coronaviruses, probably through host conversion. The bat coronavirus which has the highest gene homology to SARS-CoV-2 specifically infects deep forest bats in China whose habitat extends through the Middle East to Southern Europe. Host conversion might have occurred due to the deforestation by humans exposing wild bats to the environment they had never encountered before. SARS-CoV-2 infects cells through two mechanisms: through its receptor ACE2 with the help of enzyme TMPRSS and through membrane fusion with the help of elastases in the inflammatory condition. Obesity, hypertension, diabetes mellitus, and pulmonary diseases cause poor prognosis of COVID-19. Aging is another factor promoting poor prognosis. These diseases and aging cause low-level and persistent inflammation in humans, which can promote poor prognosis of COVID-19. Psoriasis and atopic dermatitis are the major inflammatory skin diseases. These inflammatory skin conditions, however, do not seem to cause poor prognosis for COVID-19 based on the epidemiological data accumulated so far. These mechanisms need to be elucidated.

show abstract

Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France

Abstract: Data availability statementWe used the French national health data system [Syst eme National des Donn ees de Sant e (SNDS)], which covers the entire French population (i.e. 67 million inhabitants in France).M.Z. and E.S. contributed equally to the study.

Cited by 12 publications

References 31 publications

Children with psoriasis and COVID‐19: factors associated with an unfavourable COVID‐19 course, and the impact of infection on disease progression (Chi‐PsoCov registry)

Children with psoriasis and COVID‐19: factors associated with an unfavourable COVID‐19 course, and the impact of infection on disease progression (Chi‐PsoCov registry)

Profiles of copper intrauterine devices and levonorgestrel intrauterine systems users in France in 2019: A national observational population‐based study

Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?

Contact Info

Product

Resources

About